Cargando…
Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells
Persistence of CAR-T cell function is associated with relapse rate after CAR-T therapy, while co-stimulatory agents are highly concerned with the persistence of CAR-T cells. In this study, we designed and constructed a series of BCMA-targeting second-generation CAR constructs containing CD28, 41BB,...
Autores principales: | Tan, Jingwen, Jia, Yujie, Zhou, Meixia, Fu, Chengcheng, Tuhin, Israth Jahan, Ye, Jing, Monty, Masuma Akter, Xu, Nan, Kang, Liqing, Li, Minghao, Shao, Jiaqi, Fang, Xiaoyan, Zhu, Hongjia, Yan, Lingzhi, Qu, Changju, Xue, Shengli, Jin, Zhengming, Chen, Suning, Huang, Haiwen, Xu, Yang, Chen, Jia, Miao, Miao, Tang, Xiaowen, Li, Caixia, Yan, Zhiqiang, Wu, Depei, Yu, Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974082/ https://www.ncbi.nlm.nih.gov/pubmed/35365211 http://dx.doi.org/10.1186/s13045-022-01244-0 |
Ejemplares similares
-
Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody
por: Ye, Jing, et al.
Publicado: (2022) -
Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma
por: Ping, Nana, et al.
Publicado: (2022) -
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
por: Liu, Sining, et al.
Publicado: (2023) -
Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy
por: Gu, Jingxian, et al.
Publicado: (2022) -
Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient
por: Zou, Rui, et al.
Publicado: (2023)